Price movement over the last 24 hours
Apollo Global Management Ord Shs vs TransMedics Group Inc — how do they compare? Apollo Global Management Ord Shs trades at $120 (market cap $69.38B), while TransMedics Group Inc trades at $71.23 (market cap $2.46B). The key difference: Apollo Global Management Ord Shs is far larger — about 28.2× TransMedics Group Inc's market cap, and Apollo Global Management Ord Shs pays a 1.87% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| APO | TMDX | |
|---|---|---|
Market Cap | $69.38B | $2.46B |
Sector | Financials | Technology |
52-Week High | $156.05 | $150.42 |
52-Week Low | $100.30 | $61.99 |
Enterprise Value | -$168.19B | $2.86B |
Dividend Yield | 1.87% | — |
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $120.34, up 0.42% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $1.94, beating estimates, and maintains strong analyst support with 23 buy ratings. Recent news highlights private credit growth opportunities alongside liquidity concerns in Apollo's funds.
APO's outlook is supported by earnings beats and a $149.86 consensus price target, but risks include private credit liquidity pressures and a high P/E ratio of 75.69. Investor sentiment is mixed due to ongoing fund withdrawal caps and legal investigations, though long-term growth in alternative assets remains a positive catalyst.
TransMedics Group (TMDX) trades at $71.23, down 1.33% on the day, with a bearish technical signal despite strong profitability metrics including a 27.04% net income margin and 45.22% ROE. Recent Q1 2026 earnings missed expectations, but the company is expanding its Organ Care System into Europe through a strategic investment in PAD Aviation. Analyst consensus remains bullish with a $108.71 price target, though margin pressure from expansion investments is a noted concern.
The outlook for TMDX is mixed; strong fundamentals and growth initiatives support long-term potential, but near-term execution risks and technical weakness pose challenges. Investors should weigh the company's competitive moat in transplant logistics against volatility from earnings misses and high valuation multiples during its expansion phase.
Trailing returns across standard periods
Latest headlines on both assets
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →